Eli Lilly’s record capitalization marks a historic turning point: anti-obesity drugs transform pharma into a frontier industry, amidst explosive growth, new challenges and big tech expectations.
When in November Eli Lilly has exceeded the threshold – psychological rather than financial – of the 1,000 billion dollars of capitalizationWall Street did not applaud. He looked up from the trade book and took note. Because that number is not just a peak, but a dividing line. It marks the moment in which the pharmaceutical sector ceases to be a defensive sector, reassuring and not very suitable for disposable speculation, and presents itself as frontier industrycapable of attracting capital, expectations and more solid bets than big tech. Outside the perimeter of Nasdaq Magnificent Sevenuntil yesterday he had only reached that goal Berkshire Hathawaythe patient safe of Warren Buffettthe Oracle of Omaha who retired late last year at the age of 95. Now there is a pharmaceutical. Not just any one: the American one Eli Lilly. Not Roche, not Novartis or AstraZeneca and not even the main competitor: the Danish Novo Nordisk. And this, in the silence of the official press releases, already tells a story generational defeat of the old European pharma. On the other hand, the successes of the Indianapolis multinational led since 2016 by Dave Rickstrue director of success. The point, however, is not to celebrate Lilly as if it were a brilliant start-up that stumbled into history by chance. The point is to understand why Lilly and why now. And above all, ask yourself whether the market is pricing in a new structural equilibrium or is simply anticipating too much enthusiasm about the future.
GLP-1, the new industrial category
But skill, in the markets, does not equate to invincibility. And the risk today is to confuse operational success with a sort of permanent immunity. The heart of the story is the GLP-1drugs that imitate a natural hormone and which, created for diabetes, have been found inobesity a global scale of diffusion. It’s not just a clinical question. It is an economic, social, cultural issue. Because obesity is not a niche: it is a chronic condition that concerns hundreds of millions of people. Translated into financial language: potentially infinite question. The market quickly understood that this was not a single blockbuster, but a new industrial category. So much so that today a rumor is enough – like the one about Lilly’s possible interest in the French biotech Abivax – to provoke disproportionate reactions: a leap of 20 percent in one day for a society that until then lived in the shadows. It is the side effect of expansion phases: when capital seeks a story, every detail becomes a plot.
Big tech numbers
Lilly’s numbers help explain the enthusiasm. In recent quarters the stock has continued to rise, supported by the results of Mounjaro And Zepbound. In the third quarter, net profit grew to 5.58 billion dollarsagainst i 970 million of the previous year. An increase that has little to do with pharmaceutical tradition and a lot to do with the dynamics of highly scalable technology companies. Today the stars of the Nasdaq are called Nvidia (4,500 billion capitalisation), AlphabetGoogle’s holding company (4 thousand), Apple (3,800) e Microsoft (3,600). And it is precisely here that the first uncomfortable question arises: How sustainable is this trajectory? Because if Eli Lilly is valued as a tech company today, it will also have to face, sooner or later, the same expectations and disappointments that the market reserves for the sector when growth slows. With the difference, however, that in pharmaceuticals it is impossible to think of a speculative bubble given that the demand for medicines, especially in Europe with an aging population, is destined to grow. As well as body care products.
Novo Nordisk’s decline and global competition
For years he has been the public face of the anti-obesity revolution Novo Nordisk. Ozempic And Wegovy they turned the Dane into a global star. But the market, which does not like positional income, has changed its mood. Today Eli Lilly travels beyond one trillion dollars while Novo stops around 173 billion euros and is anticipating a sharp reversal after years of increases. In the last year the stock has lost approximately 40 percent. It is no coincidence that in the autumn there was a revolution in governance: the CEO Lars Rebien Sørensen has assumed the presidency where he will remain for a period of two or three years. In his place Maziar Mike Doustdar in the meantime he started a savings plan from 8 billion Danish crowns until 2026 (one billion euros). Analysts, in fact, are starting to be less forgiving. Ubs cut its price target on Novo Nordisk, signaling growing pricing pressures and an increasingly competitive U.S. market. «A headwind of more than 25 percent on prices in 2026″, writes the bank. Translation: Volume growth may not be enough to offset margin compression.
A race that affects the entire sector
But the challenge isn’t just about Novo. The entire sector has something to do with it. For McKinseythe global market for anti-obesity drugs and related products could be worth between 120 and 280 billion dollars a year. Numbers that explain why no one wants to stay out of it. Amgen, Roche, AstraZeneca they are investing rivers of money to make up for the gap. Pfizerafter having interrupted the development of its own pill due to safety problems, has returned to the charge with an operation from 10 billion on Metsera. It is not a sign of strength, but of urgency. When the big guys buy so expensively, it’s because they fear they’ll arrive too late. Second Tazio Stornifund manager Pictet Biotech«anti-obesity drugs are only at the beginning of their life cycle». But that the real game hasn’t started yet: «The competitive advantage will be in the oral formulations». And here Lilly tries to anticipate again with a pill that promises to overcome the limits of the needle and syringe. Promises, indeed. Because until definitive data arrives, the pill remains a gamble. And the market today already seems to price its success as if it were a given.
Social impact and access risks
In the meantime the phenomenon has become social. In the United States the use of GLP-1 it has more than doubled since 2024 and contributed to the first measurable decline in obesity rates. But alongside the benefits, contradictions also emerge: high prices, unequal access, incomplete insurance coverage. The risk is that the obesity revolution becomes yet another progress reserved for those who can afford it. As he observes Matteo Ramenghi of Ubs WM Italia“the aging population offers enormous opportunities for pharmaceuticals”, but every expansion cycle also brings with it a excess of expectations. Obesity, oncology and medical devices will drive growth, yes. But not without shocks.
Beyond the number, the real challenge
And so the final question is not whether Eli Lilly you deserve a trillion. He conquered it, period. The real question is another: How much of that trillion is science, how much is strategy, and how much is anticipatory confidence in the future? The most balanced answer is to look beyond the single trimester, beyond the single drug. The history of the markets teaches that the first to enter the trillion club is not always the one who stays there the longest, but that the ability to innovate, anticipate needs And adapt to new challenges determines who stays over time. And in this sense, Lilly has already demonstrated that she possesses those qualities. Obesity has become business, yes, but also real opportunity to improve lives and health systems. With new medicines, more accessible formulations and a rapidly growing global presence, the group is not only leading the industry, but shaping it. The trillion is not just a number: it is the signal that the pharmaceutical industry can still transform itself into an engine of progress. In a world where innovation and health are increasingly intertwined, Lilly is the preview of what pharma can become. And if he can balance ambition and caution, that trillion could just be the beginning of a new era.
